New treatments in early age-related macular degeneration

This article reviews the various treatment options available as prophylactic therapy for early AMD.

Share options

Introduction

Age-related macular degeneration (AMD) is the leading cause of blindness amongst the elderly in the western world. An estimated 30% of people aged 75 years or older show at least the early manifestations of AMD, which consists of yellow deposits (drusen) and/or pigment clumps. In the UK, there are 25 000 new cases of wet AMD each year and the current intravitreal anti-VEGF therapy costs 1% of the annual £9 billion NHS budget. Currently, there is no treatment to prevent progression of the earlier stages of AMD. Prevention is better than cure and there is ongoing research into finding a preventive therapy for this disease. This article reviews the various treatment options available as prophylactic therapy for early AMD.

Login or join the College to read more.

 

Login Required

Not yet a member of the College?

Start enjoying the benefits of College membership today. Take a look at what the College can offer you and view our membership categories and rates.

More on

OK
Loading...
Loading...
Loading...